Literature DB >> 11123940

SDS-stable complex formation between native apolipoprotein E3 and beta-amyloid peptides.

G W Munson1, A E Roher, Y M Kuo, S M Gilligan, C A Reardon, G S Getz, M J LaDu.   

Abstract

Extracellular senile plaques composed predominantly of fibrillar amyloid-beta (Abeta) are a major neuropathological feature of Alzheimer's disease (AD). Genetic evidence and in vivo studies suggest that apolipoprotein E (apoE) may contribute to amyloid clearance and/or deposition. In vitro studies demonstrate that native apoE2 and E3 form an SDS-stable complex with Abeta(1-40), while apoE4 forms little such complex. Our current work extends these observations by presenting evidence that apoE3 also binds to Abeta(1-42) and with less avidity to modified species of the peptide found in senile plaque cores. These modified peptides include a form that originates at residue 3-Glu as pyroglutamyl and another with isomerization at the 1-Asp and 7-Asp positions. In addition, we used binding reactions between apoE3 and various Abeta fragments, as well as binding reactions with apoE3 and Abeta(1-40) plus Abeta fragments as competitors, to identify the domain(s) of Abeta involved in the formation of an SDS-stable complex with apoE3. Residues 13-28 of Abeta appear to be necessary, while complex formation is further enhanced by the presence of residues at the C-terminus of the peptide. These results contribute to our understanding of the biochemical basis for the SDS-stable apoE3/Abeta complex and support the hypothesis that Abeta can be transported in vivo complexed with apoE. This complex may then be cleared from the interstitial space by apoE receptors in the brain or become part of an extracellular amyloid deposit.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123940     DOI: 10.1021/bi0017475

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  High levels of homocysteine results in cerebral amyloid angiopathy in mice.

Authors:  Jian-Guo Li; Domenico Praticò
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Authors:  Tina Bilousova; Mikhail Melnik; Emily Miyoshi; Bianca L Gonzalez; Wayne W Poon; Harry V Vinters; Carol A Miller; Maria M Corrada; Claudia Kawas; Asa Hatami; Ricardo Albay; Charles Glabe; Karen H Gylys
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

3.  Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Authors:  John D Fryer; Kelly Simmons; Maia Parsadanian; Kelly R Bales; Steven M Paul; Patrick M Sullivan; David M Holtzman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

4.  Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Authors:  Leon M Tai; Tina Bilousova; Lisa Jungbauer; Stephen K Roeske; Katherine L Youmans; Chunjiang Yu; Wayne W Poon; Lindsey B Cornwell; Carol A Miller; Harry V Vinters; Linda J Van Eldik; David W Fardo; Steve Estus; Guojun Bu; Karen Hoppens Gylys; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

Review 5.  Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.

Authors:  Sadim Jawhar; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

6.  Biochemical and structural analysis of the interaction between β-amyloid and fibrinogen.

Authors:  Daria Zamolodchikov; Hanna E Berk-Rauch; Deena A Oren; Daniel S Stor; Pradeep K Singh; Masanori Kawasaki; Kazuyoshi Aso; Sidney Strickland; Hyung Jin Ahn
Journal:  Blood       Date:  2016-07-07       Impact factor: 22.113

Review 7.  The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.

Authors:  Matías B de Tullio; Laura Morelli; Eduardo M Castaño
Journal:  Prion       Date:  2008-05-01       Impact factor: 3.931

Review 8.  Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.

Authors:  Alex E Roher; Chera L Esh; Tyler A Kokjohn; Eduardo M Castaño; Gregory D Van Vickle; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Ian D Daugs; Yu-Min Kuo; Mark R Emmerling; Holly Soares; Joseph F Quinn; Jeffrey Kaye; Donald J Connor; Nina B Silverberg; Charles H Adler; James D Seward; Thomas G Beach; Marwan N Sabbagh
Journal:  Alzheimers Dement       Date:  2009-01       Impact factor: 21.566

10.  Dye label interference with RNA modification reveals 5-fluorouridine as non-covalent inhibitor.

Authors:  Felix Spenkuch; Gerald Hinze; Stefanie Kellner; Christoph Kreutz; Ronald Micura; Thomas Basché; Mark Helm
Journal:  Nucleic Acids Res       Date:  2014-10-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.